Share Price and Basic Stock Data
Last Updated: January 23, 2026, 6:03 pm
| PEG Ratio | 79.38 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Biogen Pharmachem Industries Ltd operates in the Finance & Investments sector, with its stock currently priced at ₹0.60 and a market capitalization of ₹54.2 Cr. The company has reported fluctuating revenue patterns, with sales standing at ₹2.38 Cr for the fiscal year ending March 2024, a decline from ₹2.47 Cr in the previous fiscal year. The trailing twelve months (TTM) sales recorded are ₹1.58 Cr, indicating a significant dip from prior periods. Notably, the firm experienced negative sales in several quarters, including a decline of ₹0.01 Cr in March 2023 and ₹0.09 Cr in June 2024. However, a recovery was noted in March 2025, where sales rose to ₹1.35 Cr. This erratic revenue stream, combined with operational challenges, may reflect underlying issues in market positioning and demand generation strategies.
Profitability and Efficiency Metrics
Biogen Pharmachem’s profitability has shown volatility, with a reported net profit of ₹1.72 Cr for the TTM period. The company recorded a net profit margin of 0% for March 2025, which is a stark contrast to the previous fiscal year where it stood at 0.02%. The operating profit margin (OPM) fluctuated significantly, peaking at 94.87% in March 2024 but declining to -24.17% in March 2025. This inconsistency in profitability metrics raises concerns regarding operational efficiency and cost management. The return on equity (ROE) and return on capital employed (ROCE) both stood at 0.39%, indicating a low efficiency in generating returns from shareholders’ equity and capital employed. Furthermore, the company has not recorded any interest expenses, which may suggest either a lack of debt or ineffective financial leverage.
Balance Sheet Strength and Financial Ratios
The balance sheet of Biogen Pharmachem reflects a conservative financial structure, with borrowings recorded at ₹0.00 Cr. The total assets as of March 2025 were ₹92.02 Cr, while total liabilities stood at ₹99.18 Cr, indicating a potential liquidity issue. The equity capital remained stable at ₹65.26 Cr, but reserves have shown a significant turnaround from a negative ₹10.67 Cr in March 2023 to a positive ₹26.67 Cr in March 2025. This recovery in reserves can be seen as a positive sign, yet the price-to-book value ratio of 0.68x suggests that the stock may be undervalued relative to its book value. The current ratio of 29.65x indicates strong short-term liquidity, but the efficiency ratios such as the interest coverage ratio, which remains at 0.00x, highlight the company’s inability to cover potential interest obligations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Biogen Pharmachem indicates a fully public ownership structure, with 100% of shares held by the public as of the latest reporting periods. The number of shareholders has increased from 1,90,531 in December 2022 to 2,93,327 by September 2025, suggesting growing interest and confidence among retail investors. However, the absence of institutional investors (FIIs and DIIs) raises questions regarding the stock’s appeal to larger, more stable investment entities. The fluctuations in shareholder numbers could reflect speculative trading behavior rather than long-term investment confidence. The company’s market capitalisation of ₹54.2 Cr and its low P/E ratio of 31.5 may attract value investors looking for potential upsides, yet the inconsistent financial performance could deter more risk-averse investors.
Outlook, Risks, and Final Insight
The outlook for Biogen Pharmachem Industries Ltd remains uncertain, given its historical revenue volatility and profitability challenges. The potential for recovery exists, particularly if the company can leverage its strong liquidity position and stabilize its operational metrics. However, risks such as the lack of institutional investor backing, erratic sales performance, and low profitability ratios pose significant threats to future growth. Additionally, the company’s dependence on public shareholders may lead to volatility in stock price, influenced by market sentiments rather than fundamentals. Should Biogen successfully navigate these challenges and implement effective operational strategies, it could see a resurgence in investor confidence and financial performance. Conversely, failure to address these issues may hinder its ability to attract long-term investment and sustain growth.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Shares & Stockbrokers Ltd | 11.7 Cr. | 40.0 | 57.0/36.4 | 46.9 | 44.4 | 0.00 % | 3.32 % | 1.74 % | 10.0 |
| Monarch Networth Capital Ltd | 2,179 Cr. | 274 | 455/269 | 13.6 | 111 | 0.37 % | 33.3 % | 26.2 % | 10.0 |
| Monotype India Ltd | 29.5 Cr. | 0.42 | 1.23/0.38 | 4.09 | 0.03 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 3.76 Cr. | 7.58 | 11.6/7.58 | 9.25 | 0.00 % | 3.68 % | 3.38 % | 10.0 | |
| Munoth Financial Services Ltd | 17.9 Cr. | 34.8 | 69.9/34.8 | 19.9 | 0.00 % | 2.41 % | 3.38 % | 10.0 | |
| Industry Average | 7,026.97 Cr | 1,255.91 | 66.77 | 3,844.55 | 0.38% | 21.71% | 14.20% | 7.28 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | -0.01 | 0.75 | 0.00 | 0.00 | 0.78 | -0.09 | 0.00 | 0.23 | 1.35 | 0.00 | 0.00 |
| Expenses | 0.11 | 0.03 | 0.19 | 0.34 | 0.04 | 0.03 | 0.04 | 0.07 | 0.35 | 0.54 | 0.17 | 0.20 | 0.39 |
| Operating Profit | -0.11 | -0.03 | -0.20 | 0.41 | -0.04 | -0.03 | 0.74 | -0.16 | -0.35 | -0.31 | 1.18 | -0.20 | -0.39 |
| OPM % | 54.67% | 94.87% | -134.78% | 87.41% | |||||||||
| Other Income | 2.05 | 0.33 | 0.00 | 0.00 | 0.76 | 0.09 | 0.00 | 0.00 | -0.65 | 0.00 | 0.00 | 1.54 | -0.10 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 | -0.49 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 1.94 | 0.30 | -0.20 | 0.41 | 0.72 | 0.06 | 0.74 | -0.16 | -1.00 | -0.31 | 1.18 | 1.34 | -0.49 |
| EPS in Rs | 0.03 | 0.00 | -0.00 | 0.01 | 0.01 | 0.00 | 0.01 | -0.00 | -0.02 | -0.00 | 0.02 | 0.01 | -0.01 |
Last Updated: December 27, 2025, 6:38 pm
Below is a detailed analysis of the quarterly data for Biogen Pharmachem Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Expenses, as of Sep 2025, the value is 0.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.20 Cr. (Jun 2025) to 0.39 Cr., marking an increase of 0.19 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.39 Cr.. The value appears to be declining and may need further review. It has decreased from -0.20 Cr. (Jun 2025) to -0.39 Cr., marking a decrease of 0.19 Cr..
- For OPM %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Other Income, as of Sep 2025, the value is -0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 1.54 Cr. (Jun 2025) to -0.10 Cr., marking a decrease of 1.64 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.49 Cr.. The value appears to be declining and may need further review. It has decreased from 1.34 Cr. (Jun 2025) to -0.49 Cr., marking a decrease of 1.83 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.49 Cr.. The value appears to be declining and may need further review. It has decreased from 1.34 Cr. (Jun 2025) to -0.49 Cr., marking a decrease of 1.83 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.01. The value appears to be declining and may need further review. It has decreased from 0.01 (Jun 2025) to -0.01, marking a decrease of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:03 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.95 | 0.00 | 1.62 | 2.47 | 0.00 | 2.38 | 1.20 | 1.58 |
| Expenses | 0.03 | 0.04 | 0.03 | 0.12 | 6.72 | 0.95 | 0.12 | 3.22 | 2.49 | 0.45 | 0.45 | 1.49 | 1.30 |
| Operating Profit | -0.03 | -0.04 | -0.03 | -0.12 | -6.61 | 0.00 | -0.12 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 | 0.28 |
| OPM % | -6,009.09% | 0.00% | -98.77% | -0.81% | 81.09% | -24.17% | 17.72% | ||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.01 | 0.91 | 0.00 | 0.00 | 1.44 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.13 | -0.14 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.13 | -0.13 | -0.03 | -0.12 | -6.56 | 0.00 | -0.12 | -1.60 | -0.01 | 0.46 | 1.93 | -0.29 | 1.72 |
| EPS in Rs | -0.00 | -0.00 | -0.00 | -0.00 | -0.10 | 0.00 | -0.00 | -0.02 | -0.00 | 0.01 | 0.03 | -0.00 | 0.02 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 76.92% | -300.00% | -5366.67% | 100.00% | -1233.33% | 99.38% | 4700.00% | 319.57% | -115.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.92% | -376.92% | -5066.67% | 5466.67% | -1333.33% | 1332.71% | 4600.62% | -4380.43% | -434.59% |
Biogen Pharmachem Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -21% |
| TTM: | 352% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 30% |
| 3 Years: | -2% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 0% |
| 3 Years: | 1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: December 4, 2025, 2:32 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 65.26 | 90.26 |
| Reserves | -4.14 | -4.27 | -4.30 | -4.42 | -10.98 | -10.99 | -9.51 | -11.12 | -11.13 | -10.67 | -8.74 | 26.67 | 8.82 |
| Borrowings | 57.21 | 10.00 | 6.21 | 0.72 | 0.01 | 0.63 | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 4.93 | 2.49 | 1.64 | 1.69 | 1.64 | 2.73 | 0.03 | 0.11 | 0.82 | 0.24 | 0.30 | 0.09 | 0.10 |
| Total Liabilities | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.18 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 60.86 | 43.78 | 26.69 | 22.39 | 3.52 | 6.25 | 6.45 | 9.49 | 6.95 | 8.85 | 5.44 | 23.84 | 21.37 |
| Other Assets | 62.40 | 29.70 | 42.12 | 40.86 | 52.41 | 51.38 | 49.64 | 44.76 | 48.00 | 45.98 | 51.38 | 68.18 | 77.81 |
| Total Assets | 123.26 | 73.48 | 68.81 | 63.25 | 55.93 | 57.63 | 56.09 | 54.25 | 54.95 | 54.83 | 56.82 | 92.02 | 99.18 |
Below is a detailed analysis of the balance sheet data for Biogen Pharmachem Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 90.26 Cr.. The value appears strong and on an upward trend. It has increased from 65.26 Cr. (Mar 2025) to 90.26 Cr., marking an increase of 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 8.82 Cr.. The value appears to be declining and may need further review. It has decreased from 26.67 Cr. (Mar 2025) to 8.82 Cr., marking a decrease of 17.85 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Sep 2025, the value is 99.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 92.02 Cr. (Mar 2025) to 99.18 Cr., marking an increase of 7.16 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 21.37 Cr.. The value appears to be declining and may need further review. It has decreased from 23.84 Cr. (Mar 2025) to 21.37 Cr., marking a decrease of 2.47 Cr..
- For Other Assets, as of Sep 2025, the value is 77.81 Cr.. The value appears strong and on an upward trend. It has increased from 68.18 Cr. (Mar 2025) to 77.81 Cr., marking an increase of 9.63 Cr..
- For Total Assets, as of Sep 2025, the value is 99.18 Cr.. The value appears strong and on an upward trend. It has increased from 92.02 Cr. (Mar 2025) to 99.18 Cr., marking an increase of 7.16 Cr..
Notably, the Reserves (8.82 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -57.24 | -10.04 | -6.24 | -0.84 | -6.62 | -0.63 | -0.43 | -1.60 | -0.02 | -0.45 | 1.93 | -0.29 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Inventory Days | 0.00 | 0.00 | 0.00 | |||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 23,326.82 | 3,085.21 | 572.28 | 0.00 | 0.00 | 0.00 | ||||||
| Working Capital Days | 23,194.09 | 2,651.05 | 549.75 | 152.21 | -35.27 | 170.33 | ||||||
| ROCE % | -0.14% | -0.15% | -0.04% | -0.19% | -11.32% | 0.00% | -0.22% | -2.90% | -0.02% | -0.37% | 3.47% | -0.39% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Diluted EPS (Rs.) | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 |
| Cash EPS (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.41 | 0.86 | 0.83 | 0.82 | 0.82 |
| Revenue From Operations / Share (Rs.) | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| PBDIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBIT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBT / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| Net Profit / Share (Rs.) | 0.00 | 0.02 | 0.01 | 0.00 | -0.02 |
| PBDIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBIT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| PBT Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Net Profit Margin (%) | 0.00 | 0.00 | 0.00 | -0.34 | -98.80 |
| Return on Networth / Equity (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return on Capital Employeed (%) | -0.31 | 3.41 | 0.83 | -0.01 | -2.96 |
| Return On Assets (%) | -0.31 | 3.39 | 0.83 | -0.01 | -2.95 |
| Asset Turnover Ratio (%) | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Current Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Quick Ratio (X) | 29.65 | 0.30 | 0.64 | 2.37 | 23.64 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | 0.00 | -46.77 | -34255.66 |
| Enterprise Value (Cr.) | 60.63 | 69.16 | 38.37 | 91.28 | 13.70 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.89 | 8.44 |
| EV / EBITDA (X) | -207.15 | 35.82 | 84.25 | -10849.12 | -8.54 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.93 | 8.45 |
| Price / BV (X) | 0.68 | 1.22 | 0.70 | 1.69 | 0.25 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 36.94 | 8.47 |
| EarningsYield | 0.00 | 0.02 | 0.01 | 0.00 | -0.11 |
After reviewing the key financial ratios for Biogen Pharmachem Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.00, marking a decrease of 0.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.41. It has increased from 0.86 (Mar 24) to 1.41, marking an increase of 0.55.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 15. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 10. It has decreased from 3.41 (Mar 24) to -0.31, marking a decrease of 3.72.
- For Return On Assets (%), as of Mar 25, the value is -0.31. This value is below the healthy minimum of 5. It has decreased from 3.39 (Mar 24) to -0.31, marking a decrease of 3.70.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Current Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 3. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Quick Ratio (X), as of Mar 25, the value is 29.65. This value exceeds the healthy maximum of 2. It has increased from 0.30 (Mar 24) to 29.65, marking an increase of 29.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60.63. It has decreased from 69.16 (Mar 24) to 60.63, marking a decrease of 8.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is -207.15. This value is below the healthy minimum of 5. It has decreased from 35.82 (Mar 24) to -207.15, marking a decrease of 242.97.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 24) to 0.68, marking a decrease of 0.54.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biogen Pharmachem Industries Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.31% (Industry Average ROCE: 21.71%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.31% (Industry Average ROE: 14.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 29.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 31.5 (Industry average Stock P/E: 66.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Finance & Investments | Shop No. 8, First Floor, Makers - 1 Building, Rajkot Gujarat 360001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Kelash Bunkar | WholeTime Director & CFO |
| Mr. Chandrakant Govindbhai Parmar | Director |
| Mr. Chhayaben Parmar | Director |
| Mr. Narendrakumar Vaniya | Director |
| Mr. Aman Patel | Director |
| Mr. Harshadkumar Rathod | Director |
FAQ
What is the intrinsic value of Biogen Pharmachem Industries Ltd?
Biogen Pharmachem Industries Ltd's intrinsic value (as of 27 January 2026) is ₹0.11 which is 81.67% lower the current market price of ₹0.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹54.2 Cr. market cap, FY2025-2026 high/low of ₹1.19/0.57, reserves of ₹8.82 Cr, and liabilities of ₹99.18 Cr.
What is the Market Cap of Biogen Pharmachem Industries Ltd?
The Market Cap of Biogen Pharmachem Industries Ltd is 54.2 Cr..
What is the current Stock Price of Biogen Pharmachem Industries Ltd as on 27 January 2026?
The current stock price of Biogen Pharmachem Industries Ltd as on 27 January 2026 is ₹0.60.
What is the High / Low of Biogen Pharmachem Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biogen Pharmachem Industries Ltd stocks is ₹1.19/0.57.
What is the Stock P/E of Biogen Pharmachem Industries Ltd?
The Stock P/E of Biogen Pharmachem Industries Ltd is 31.5.
What is the Book Value of Biogen Pharmachem Industries Ltd?
The Book Value of Biogen Pharmachem Industries Ltd is 1.10.
What is the Dividend Yield of Biogen Pharmachem Industries Ltd?
The Dividend Yield of Biogen Pharmachem Industries Ltd is 0.00 %.
What is the ROCE of Biogen Pharmachem Industries Ltd?
The ROCE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the ROE of Biogen Pharmachem Industries Ltd?
The ROE of Biogen Pharmachem Industries Ltd is 0.39 %.
What is the Face Value of Biogen Pharmachem Industries Ltd?
The Face Value of Biogen Pharmachem Industries Ltd is 1.00.